What is the recommended acute management and secondary prevention strategy for an adult patient presenting with an ischemic stroke?

Acute Ischemic Stroke Management

For acute ischemic stroke, immediately administer IV alteplase (0.9 mg/kg, max 90 mg) within 4.5 hours of symptom onset for eligible patients, followed by endovascular thrombectomy for large vessel occlusions, and initiate dual antiplatelet therapy (aspirin plus clopidogrel) within 12-24 hours for minor strokes (NIHSS ≤3) or high-risk TIA, continuing for 21-90 days before transitioning to single antiplatelet therapy. 1, 2, 3

Acute Phase Management (First 4.5 Hours)

Immediate Reperfusion Therapy

IV Thrombolysis:

• Administer alteplase 0.9 mg/kg (maximum 90 mg) over 60 minutes with 10% as initial bolus over 1 minute 1, 3
• Time windows:
  • 0-3 hours: Class I, Level A recommendation - strongest evidence 1
  • 3-4.5 hours: Class I, Level B-R recommendation 1
  • Wake-up strokes with DWI-FLAIR mismatch on MRI can receive thrombolysis beyond 4.5 hours 4

Critical eligibility criteria to verify:

• Disabling stroke symptoms (any NIHSS score qualifies if disabling)
• No intracranial hemorrhage on CT/MRI
• Blood glucose >60 mg/dL (treat hypoglycemia first) 1
• Blood pressure <185/110 mmHg before treatment 1

Common pitfall: The 2018 guidelines removed many previous absolute contraindications. Age >80, prior stroke plus diabetes, and NIHSS >25 are no longer absolute contraindications despite ECASS-III exclusions 1. The 2026 update further liberalized contraindications 3.

Endovascular Thrombectomy

Perform mechanical thrombectomy for large vessel occlusions, with expanded time windows now supported by recent evidence 3. The 2026 guidelines provide specific guidance for medium vessel occlusions, which were previously less clearly addressed 5, 3.

Post-Acute Management (First 24-48 Hours)

Physiologic Parameters

Blood glucose control:

• Target range: 140-180 mg/dL 1
• Avoid hypoglycemia (<60 mg/dL) - treat immediately 1
• Persistent hyperglycemia in first 24 hours worsens outcomes 1

Temperature management:

• Maintain normothermia; both hypothermia (<37°C) and fever (>39°C) increase mortality 1
• Do NOT induce therapeutic hypothermia outside clinical trials 1

Blood pressure:

• Post-thrombolysis: maintain <180/105 mmHg for 24 hours 1

Stroke Unit Care

Transfer all patients to a dedicated stroke unit - this has the highest agreement among experts for improving outcomes 6. Stroke unit care reduces mortality and disability more than any other single intervention.

Secondary Prevention (Initiated Within 48 Hours)

Antiplatelet Therapy Strategy

For noncardioembolic stroke, the approach depends on stroke severity:

Minor stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4):

• Initiate dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel within 12-24 hours 2
• Continue DAPT for 21-90 days, then transition to single antiplatelet therapy 2
• This is a Class 1 recommendation with strong evidence from recent trials 2

Moderate-severe stroke or after 90 days:

• Single antiplatelet therapy: aspirin 50-325 mg daily, clopidogrel 75 mg daily, or aspirin 25 mg + extended-release dipyridamole 200 mg twice daily 2

Critical warning: Do NOT continue DAPT beyond 90 days - excess hemorrhage risk without benefit 2. Triple antiplatelet therapy is contraindicated 2.

Alternative for NIHSS ≤5 or ABCD2 ≥6:

• Ticagrelor plus aspirin for 30 days may be considered but carries increased bleeding risk including intracranial hemorrhage 2

Cardioembolic Stroke (Atrial Fibrillation)

Anticoagulation is superior to antiplatelet therapy for atrial fibrillation-related stroke 2. Timing of initiation depends on infarct size and hemorrhagic transformation risk.

Additional Secondary Prevention

Mandatory interventions:

• Statin therapy regardless of baseline cholesterol 6
• ECG and cardiac evaluation to identify atrial fibrillation 6
• Non-invasive vascular imaging (carotid ultrasound or CTA) 6
• Deep venous thrombosis prophylaxis 6
• Blood pressure control to <130/80 mmHg 7
• Dysphagia screening before oral intake 3

Mechanism Evaluation

Complete workup to determine stroke etiology:

• Prolonged cardiac monitoring (≥24 hours) to detect paroxysmal atrial fibrillation 7
• Carotid imaging for stenosis assessment
• Consider patent foramen ovale evaluation in cryptogenic stroke, especially younger patients 7

Key Algorithmic Decision Points

1. Time from symptom onset <4.5 hours + no hemorrhage on CT → Give IV alteplase immediately
2. Large vessel occlusion identified → Proceed to thrombectomy (can be done with or after thrombolysis)
3. NIHSS ≤3 or high-risk TIA → Start DAPT within 24 hours for 21-90 days
4. NIHSS >3 or after 90 days DAPT → Single antiplatelet therapy
5. Atrial fibrillation identified → Anticoagulation (not antiplatelet therapy)
6. Significant carotid stenosis → Consider endarterectomy or stenting

Critical Pitfalls to Avoid

• Do not delay thrombolysis for extensive workup - door-to-needle time is critical
• Do not withhold consent process - when patient cannot consent and no proxy available, proceed with thrombolysis if otherwise eligible 1
• Do not use lower alteplase doses - 0.6 mg/kg was proven inferior 1
• Do not continue DAPT beyond 90 days - hemorrhage risk outweighs benefit 2
• Do not forget glucose monitoring - both hyper- and hypoglycemia worsen outcomes 1

The 2026 AHA/ASA guidelines 3 represent the most current evidence and include important updates on thrombolytic eligibility, pediatric considerations, and medium vessel occlusion management, building upon the solid foundation established in 2018 1 and refined in 2021 2.